Gallery of Awardees
The CoM Office of Research understands the challenges of successfully competing for funding to support faculty research programs and we want to celebrate our new awardees. We publicize those faculty who have been awarded external grants of $100,000/yr. or more in direct costs in a Gallery of Awardees. The Gallery is displayed in the CARE/Crawley Atrium and electronic posters will be posted on CoM digital signage and on Twitter. Besides celebrating our successful investigators, a brief synopsis of the award goals and pictures of the faculty are also included on the announcement so that other faculty interested in potential collaborations or seminars by our researchers can contact them. Please note that it may take 2-3 months before the Gallery of Awardees recognizes new awards due to the processing of data.
Gallery of Awardees

National Institute of Neurological Disorders and Stroke RF1
Title: APRISE Dementia (Assessing Population-based Radiological brain health in Stroke Epidemiology-Dementia)
Award Period: 8/15/2020- 5/31/2024
Award Sum: $1,963,399.00
Project Summary: This research aims to create a prediction model of post stroke dementia (PSD) incorporating imaging parameters in a biracial ischemic stroke/hemorrhagic stroke/TIA population using state-of-the-art modeling approaches. Researchers hypothesize that diagnosis of PSD (within five years from index stroke event) will be better predicted by incorporating imaging parameters compared to traditional vascular risk factors alone.

Michael J. Fox Foundation for Parkinson's Research Award
Title: The Parkinson’s Progression Markers Initiative
Award Period: 11/1/2020- 10/31/2033
Award Sum: $2,152,338.00
Project Summary: The “Parkinson’s Progression Markers Initiative” is an observational study designed to evaluate and validate biomarkers of progression in patients with Parkinson’s disease, conducted at a network of clinical sites around the world, funded by the Michael J. Fox Foundation. Clinical, imaging and biosample data are used to define biomarkers that may serve to guide further therapeutic efforts.

National Institute of General Medical Sciences R25
Title: Biomedical Postbaccalaureate Research Education Program
Project Period: 9/21/2020- 8/31/2025
Award Sum: $1,575,141.00
Project Summary: The University of Cincinnati PREP program (PREP@UC) will provide training to prepare recent college graduates from underrepresented minority groups, disadvantaged backgrounds or with disabilities for entry into a biomedical doctoral program and successful completion of that program. PREP@UC will provide intensive mentoring, research training and an individually tailored program of academic preparation. The scholars will spend 75% of their time performing research and the remaining 25% time on other educational and mentoring activities.
Carl Fichtenbaum, MD, Professor, Department of Internal Medicine, Division of Infectious Diseases
National Institute of Allergy and Infectious Diseases Award
Title: COVID-19 Prevention Network
Award Period: 7/1/2020- 11/30/2020
Award Sum: $380,075.00
Project Summary: To help expand existing site capacity, these funds will be used to expand clinical, laboratory and staffing capacity to participate in large, Phase III vaccine or monoclonal antibody efficacy trials with large numbers of study participants. This capacity expansion includes community engagement and outreach to support enrollment and retention efforts.
National Institute of Allergy and Infectious Diseases Award
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV
Award Period: 7/1/2020- 11/30/2021
Award Sum: $475,500.00
Project Summary: This study is designed to assess the efficacy and safety of co-administered REGN10933+REGN10987 combination therapy ("REGN10933+REGN10987") to reduce the proportion of SARS-CoV-2 infections and prevent the development of COVID-19 disease (symptomatic SARS-CoV2 infect ion), after household exposure to individuals with SARS-CoV-2 infection. Safety, tolerability, pharmacokinetics, and immunogenicity of REGN10933+REGN10987 will also be evaluated.
National Institute of Allergy and Infectious Diseases Award
Title: Phase 3, SARS-oV-2 Vaccine (Moderna TX, Inc.)
Award Period: 7/1/2020- 6/30/2022
Award Sum: $6,539,000.00
Project Summary: The study is designed to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and evaluate the safety and reactogenicity of 2 injections of mRNA-1273 given 28 days apart.

Title: Biomedical Postbaccalaureate Research Education Program
Project Period: 9/21/2020- 8/31/2025
Award Sum: $1,575,141.00
Project Summary: The University of Cincinnati PREP program (PREP@UC) will provide training to prepare recent college graduates from underrepresented minority groups, disadvantaged backgrounds or with disabilities for entry into a biomedical doctoral program and successful completion of that program. PREP@UC will provide intensive mentoring, research training and an individually tailored program of academic preparation. The scholars will spend 75% of their time performing research and the remaining 25% time on other educational and mentoring activities.
Shriners Hospitals for Children Ceramide
Title: Regulatory Role upon Neutrophil Chemotaxis after Burn Injury
Award Period: 1/1/2020- 12/31/2022
Award Sum:$749,913.00
Summary of Project: These studies will identify how burn injury disrupts Asm-mediated regulatory pathways necessary for functional neutrophil trafficking. This will enable potential therapeutics that can alter Asm activity and/or ceramide levels to beneficially regulate the host inflammatory response following burn.
National Institute of General Medical Sciences Sub Award
Title: Stratifying Patient Immune Endotypes in Sepsis (SPIES Study)
Award Period: 9/5/2020- 6/30/2025
Award Sum: $798,995.00
Project Summary: Researchers will assess whether stimulated T cell production of IFN-γ and stimulated monocyte production of TNFα, as quantitated by ELISpot, better predicts infectious and long-term outcomes in sepsis survivors than common static measurements based on protein levels, expression and nucleic acid concentrations; and to employ ELISpot assessment of IFN-γ production by T-cells and TNFα production by monocytes from sepsis survivors to examine ex vivo the comparative efficacy of different immune stimulants to reverse sepsis-induced immunosuppression.

National Institute of Neurological Disorders and Stroke T32
Title: Cerebrovascular Fellowship Training Program
Award Period: 7/15/2020- 6/30/2025
Award Sum: $1,652,143.00
Summary of Project: This T-32 program has been training neurologists for 22 years and emergency physicians formally for 16 years with the goal of producing academic leaders and clinical researchers in the area of cerebrovascular disease and neurocritical care. The training program includes extensive hands-on experience in clinical research and trials within a broad array of NIH-funded, T-2-focused, translational research. The program includes close mentoring, well-defined course work, and unique training in the evaluation and treatment of patients with acute stroke and neurocritical care.
National Institute of Neurological Disorders and Stroke U01
Title: ERICH-GENE
Project Period: 9/1/2020- 6/30/2025
Award Sum: $9,817,830.00
Project Summary: If successful, researchers will have identified risk factors for intracerebral hemorrhage (ICH), subtypes by location and across cerebral small vessel disease neuroimaging features, which will be valuable as targets for rational therapeutic development. Researchers will also have built polygenic risk scores for ICH risk and outcome, as a tool to stratify individuals by ICH risk and provide prognostic information on outcomes.
National Institute of Neurological Disorders and Stroke R01
Title: Recovery of StrokE – Longitudinal Assessment with Neuroimaging
Award Period: 12/15/2020- 11/30/2025
Award Sum: $3,127,471.00
Project Summary: This research will aims to determine if progressive cognitive impairment correlates with an increase in markers of cerebral small vessel disease and cerebral amyloid angiopathy, if inflammation as measured by RNA-sequencing markers of inflammation correlates with progressive cognitive impairment, and identify novel neuroimaging markers associated with progressive cognitive decline.

Food and Drug Administration R01
Title: Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action in pancreatic cancer
Project Period: 9/10/2020- 7/31/2024
Award Sum: $1,922,232.00
Project Summary: This is a phase I/II clinical trial to assess the efficacy and safety of ABTL0812 in combination with the standard of care chemotherapy gemcitabine and nab-paclitaxel in patients with advanced metastatic PaC at first line therapy.

National Heart, Lung and Blood Institute DP2
Title: Eavesdropping on heart-brain conversations during sleep for early detection and prevention of fatal cardiovascular disease
Award Period: 8/19/2020- 4/30/2025
Award Sum: $2,407,500.00
Project Summary: The research goal of this project is to determine remodeling of vagal signaling and autonomic-redox coupling in the heart on EEG and ECG signatures over progression of CV pathology. The research hypotheses that vagal afferents increase signal transmission to the cortex as vagal innervation density increases in the left ventricle.
Department of the Army Medical Research Acquisition Activity Award
Title: Novel sex-specific strategy for tuning the fight or flight reflex to reduce oxidative stress, reduce ventricular tachyarrhythmias and prevent sudden cardiac death
Award Period: 8/1/2020- 7/31/2021
Award Sum: $197,567.00
Project Summary: The research goal is to enhance cardiac function while reducing the risk of sudden cardiac death in a personalized manner. Researchers use gene transfer, optogenetics, implantable neurophotonic nanotechnology, and computationally-efficient artificial intelligence algorithms to continuously tune the flight-or-flight stress response by automated comparisons of historical responses and events in an individual. This system progressively tailors the stress response to achieve the highest order of functional optimization in a safe, effective and personalized manner.

MBX Biosciences, Inc Award
Title: MBX Biosciences Sponsored Research Agreement
Project Period: 8/8/2020- 8/8/2021
Award Sum: $305,171.00
Project Summary: The goal of this project is to evaluate in preclinical rodent models the feasibility of applying recent advances in medicinal chemistry to generate peptide-based therapeutics with a range of pharmacokinetic and pharmacodynamic properties suitable for the treatment of diseases pertaining to atypical hypoglycemia or hypoparathyroidism.

National Heart, Lung and Blood Institute K23
Title: Platelets and Hemostatic Factors as Facilitators of the Inflammatory Response Following Transcatheter Aortic Valve Replacement
Award Period: 7/1/2020- 6/30/2025
Award Sum: $898,021.00
Project Summary: These studies are significant and innovative in that they will provide a mechanistic understanding of the cross-talk between the hemostatic factors, platelets and inflammatory systems in patients undergoing TAVR. The resulting findings from this study may provide a foundation for newer generation antithrombotic strategies, such as targeting contact factors or thrombin receptors, to optimize outcomes following transcatheter heart valve procedures.

National Heart, Lung and Blood Institute Sub Award
Title: The Molecular and Genetic Pathogenesis of LAM
Award Period: 3/1/2020- 2/28/2025
Award Sum: $561,750.00
Project Summary: Researchers will determine the relative effect of varying levels of sirolimus on S6 phosphorylation in peripheral lymphocytes at baseline 1 hr, 12 hr and 24hr, and on VEGF-D over time. They will identify and validate additional mTOR dependent biomarkers through examination of the secretome generated by ScRNAseq of lungs from patients who were on, or not on sirolimus at time of transplant, and determine the relative effects of sirolimus on those markers in study patients.

Department of Labor Award Training
Title: Capacity Building in Trenching and Excavation
Project Period:9/30/2020- 9/30/2021
Award Sum: $162,000.00
Project Summary: The University of Cincinnati Continuing Education Program continues to build new training capacity by providing training in Trenching and Excavation Safety to a total of 400 workers and employers in the construction industry.
.tmb-small.jpg?sfvrsn=20f2311c_1)
Centers for Disease Control and Prevention R21
Title: Circulating Cell-free Antigens for Monitoring of Machining Fluids
Project Period: 9/30/2020- 9/29/2022
Award Sum: $214,998.00
Project Summary: This research will identify circulating cell-free mycobacterial antigens (and their key epitopes) predominant in field metalworking fluids (MWF) and designing of a multiplex immunoassay platform for routine fluid monitoring targeting the cf mycobacterial antigens (epitopes) in industrial in-use MWF.

Department of the Army Medical Research Acquisition Activity Award
Title: Dysregulation of sphingolipid metabolism and actions in tuberous sclerosis complex
Award Period: 9/1/2020- 8/31/2023
Award Sum:$722,250.00
Project Summary: This research addresses the basic inadequacy of current tuberous sclerosis complex (TSC) TSC therapy and, therefore, has the potential for a marked and fundamental long-term impact on treatment of patients with TSC. Importantly, by identifying the pathways that might be used by rapamycin and the ones that are activated when rapamycin stops working, new therapies distinct from rapamycin may be discovered that are more effective than this drug and that are, unlike rapamycin, curative.
National Heart, Lung and Blood Institute Sub Award
Title: Uterine signaling networks in the pathogenesis of pulmonary lymphangioleiomyomatosis (LAM).
Project Period: 7/21/2020- 6/30/2024
Award Sum: $1,544,427.00
Project Summary: The overall goal of this project is to identify direct HOX/PBX1 targets and understand their disease promoting mechanism(s) in the LAM lung niche, thereby informing the development of novel remission-inducing therapeutic strategies for LAM patients.
Physiology National Institute on Drug Abuse K01
Title: Recruitment of Endocannabinoid Signaling in the Ventral Tegmental Area and Stress Induced Escalation of Cocaine Intake
Award Period: 5/1/2020- 4/30/2021
Award Sum: $136,469.00
Project Summary: This research tests the novel hypothesis that repeated stress at the time of cocaine self-administration recruits the endocannabinoids (eCB) system in the intra-ventral tegmental area (VTA) to regulate dopamine neuron activity and output which ultimately results in expression of escalating patterns of cocaine use. In order to test this hypothesis, researchers will utilize behavioral, neurochemical, and neurophysiological techniques to assess the involvement of the eCB system in the influence of stress on cocaine use.

National Institute of Child Health and Human Development Sub Award
Title: Improving the Effectiveness and Safety of Escitalopram in Pediatric Anxiety Disorders Using Pharmacogenetically-guided Dosing
Award Period: 9/21/2020- 6/30/2021
Award Sum: $346,985.00
Project Summary: This research aims to test how pharmacogenetically-guided treatment of escitalopram, a commonly used antidepressant, influences efficacy and tolerability in pediatric patients with anxiety disorders. Researchers will measure the response after 10 weeks of treatment with the Pediatric Anxiety Rating Scale, a validated measure of anxiety symptoms in children. At the conclusion of this study, clinicians, patients, parents, and payers will have the necessary evidence to show whether there is clinical utility of pharmacogenetic-guided escitalopram dosing in youth with anxiety disorders.
.tmb-small.jpg?sfvrsn=b275c6af_1)
Department of the Army Medical Research Acquisition Activity Award
Title: Rapid Ketone Infusion to Prevent Brain Energy Depletion and Secondary Brain Injury in Severe TBI with Hemorrhagic Shock
Project Period: 9/1/2020- 8/31/2022
Award Sum: $723,710.00
Project Summary: The goal of these studies is to determine whether providing “brain food” that can circumvent obstacles to glucose metabolism that occur after TBI will prevent metabolic crisis and the spread of damage into undamaged brain tissue adjacent to the injury. Researchers also suspect that providing metabolic support after severe injury will decrease the incidence of coagulopathic complications.

National Institute of Neurological Disorders and Stroke R01
Title: Regulation of neural stem cells and neurogenesis by autophagy genes
Award Period: 9/1/2020- 6/30/2025
Award Sum: $1,896,967.00
Project Summary: This research will significantly advance our understanding of the regulation of neural progenitor/stem cells and neurogenesis by autophagy genes that may contribute to future design of effective therapies for neurodegenerative and other related diseases.

American Heart Association Award
Title: Serial RNA-seq in Acute ICH Patients: Association with 90-day Outcomes and Identification of Novel Treatment Targets
Award Period: 1/1/2021- 12/31/2023
Award Sum: $300,000.00
Project Summary: The research will identify differentially expressed genes (DEGs) and enriched biological pathways associated with 90-day (+/- 14 days) ICH clinical outcome, identify dynamic changes over time in DEGs and enriched biological pathways in the serial samples from ICH patients, and compare DEGs and enriched biological pathways in ICH patients with matched controls to identify genes induced by ICH and to explore ethnic/racial and sex differences in those genes. This research has the potential for significant impact through identification of new ICH therapeutic targets amenable to treatment with immunomodulatory medications.

National Institute of Allergy and Infectious Diseases Sub Award
Title: SARS-CoV-2 Prevalence Study
Award Period: 8/1/2020- 7/31/2021
Award Sum: $1,748,107.00
Project Summary: This study is an evaluation of communities throughout the country, including Cincinnati, OH. It will evaluate the extent of COVID-19; assess knowledge, attitudes and behaviors related to SARS-CoV-2 and COVID-19; model the potential impact of different prevention interventions; and guide future SARS-CoV-2 prevention studies and COVID-19 treatment studies in these communities. It will also provide valuable samples for important laboratory assessments related to the acquisition of SARS-CoV-2 and impact of the COVID-19 pandemic.

National Institute of Neurological Disorders and Stroke R21
Title: Role of Gucy2d in Spinal Nociceptive Processing
Project Period: 9/15/2020- 9/14/2022
Award Sum: $453,653.00
Project Summary: This research will have a positive impact on public health by providing valuable insight into new candidate approaches to restrict the output of the spinal nociceptive network without unwanted side effects on sensorimotor processing, cognitive function, emotional regulation or reward-seeking behavior. By identifying Gucy2d (encoding the membrane-bound guanylate cyclase GC-D) as a novel marker of a highly specific subset of inhibitory spinal dorsal horn interneurons that are dedicated to the suppression of pain and itch, these studies will raise the possibility that the design of new pharmacological approaches to selectively enhance the activity of the GC-D neuronal population may yield improved pain and itch relief with fewer adverse side effects that often result from the widespread distribution of a given therapeutic target across the nervous system.
.tmb-small.jpg?sfvrsn=47fdbaa8_1)
Department of the Air Force Award
Title: US Air Force Research Laboratory COVID-19 Breath Analysis Activity
Award Period: 7/28/2020- 11/16/2021
Award Sum: $228,170.00
Project Summary: The overall objective is to provide research project support and nasopharyngeal testing and analysis capability to the Air Force Research Laboratory for its COVID-19 study.

Department of Treasury Award
Title: Early Intervention Program: COVID-19 Testing, Reporting, and Surveillance
Award Period:7/1/2020- 12/30/2020
Award Sum:$7,611,499.00
Project Summary: The purpose of this overall project is to increase capacity of testing in Hamilton County, OH, identify cases of COVID-19 within the community, specifically more vulnerable & densely congregated populations, conduct serological testing and other studies to understand the percent previously infected and asymptomatically infected, and to effectively respond to and contain outbreaks before they spread to create regional impact

Department of the Army Award
Title: Convalescent Plasma to Stem Coronavirus
Project Period: 6/8/2020- 5/31/2021
Award Sum: $761,963.00
Project Summary: This is a randomized, double-blind, controlled, phase 2 study comparing the efficacy and safety of human coronavirus immune plasma vs. control (SARS-CoV-2 non-immune) plasma among outpatients with symptomatic COVID-19.

Oluwole Oladimeji Awosika, MD, Assistant Professor, Department of Neurology and Rehabilitation Medicine
American Academy of Neurology Career Development Award
Title: “Taking Steps Backward to Move Forward: A Novel Neurorehabilitative Approach in Stroke Locomotor Recovery”
Award Period: 7/1/2020- 6/30/2023
Total Award Sum: $450,000.00
The long-term goal of this study is to determine non-invasive and exercise-based approaches to maximize walking recovery after stroke. The immediate objective of this study is to investigate backward locomotion (non-bodyweight supported) treadmill training (BLT) as a novel exercise-based neurorehabilitative approach for improving overground walking in stroke survivors. The rationale for the proposed research is its expectation to determine the efficacy of BLT, investigate the biomechanical changes associated with BLT specific to this population, and determine the key temporal-spatial and biomechanical metrics that best predict walking recovery.

National Heart, Lung and Blood Institute R01
Title: Regulators of extracellular matrix production during cardiac development and disease
Project Period: 8/20/2020- 7/31/2025
Award Sum: $2,021,562.00
Project Summary: Cardiac fibrosis is a grim consequence for almost all myocardial injuries, currently with no cure in sight. To date, studies failed to identify therapeutic targets mainly due to the heterogeneity in fibroblast biology between disease types and even between various anatomical regions in the heart. This research will utilize newly developed in vivo genetic tools to rigorously interrogate all of the extracellular matrix-producing fibroblasts within the heart in order to find common and disease-specific mechanisms underlying cardiac fibrosis.

National Heart, Lung and Blood Institute Sub Award
Title: ACTIV-IV Inpatient Platform
Award Period: 11/16/2020- 5/15/2021
Award Sum: $3,831,601.00
Project Summary: The Acute Inpatient study is a multicenter, adaptive, randomized open label platform trial to compare the effectiveness of antithrombotic strategies for the prevention of adverse outcomes in COVID-19 positive inpatients. The goal of the study is to determine the most effective antithrombotic strategies for organ support and reducing death, and to assess the safety of those antithrombotic strategies.
.tmb-small.jpg?sfvrsn=4b13dfc8_1)
National Institute of Arthritis, Musculoskeletal and Skin Disease R01
Title: Slow myosin binding protein-C in skeletal muscle physiology
Award Period: 8/15/2020- 7/31/2025
Award Sum: $2,317,304.00
Project Summary: The long-term goal of this research is to understand the molecular mechanisms that underlie reduced contractility in muscle disease and identify novel therapeutic targets. Specifically, this research will define the role of slow myosin binding protein-C in regulating skeletal muscle function using four different unique mouse models. The outcome of this translational study will shed light on the pathological mechanisms leading to structural and contractile dysfunction in distal arthrogryposis type 1 and lethal congenital contracture syndrome type 4 diseases, and determine whether skeletal myosin binding protein-C isoforms constitute a valid target for intervention in muscle disease.

National Heart, Lung and Blood Institute R01
Title: The Molecular Basis for the Role of Apolipoprotein A-II in Cholesterol and Triglyceride Metabolism
Award Period: 12/15/2020- 11/30/2024
Award Sum: $1,940,628.00
Project Summary: An important goal will be to identify the apolipoprotein (apoA-II) sequences responsible with an eye toward developing cholesterol efflux boosting therapeutics. Using human proteins in human plasma-based experiments, researchers will determine how apoA-II affects the composition and structure of other VLDL proteins and assess the consequences with respect to activation of lipoprotein lipase and binding to cell surface receptors responsible for its plasma clearance.

Physiology National Institute of Nursing Research R01
Title: Identification of causal factors underlying cognitive deficits in a mouse model of childhood leukemia survival
Project Period: 9/7/2020- 6/30/2025
Award Sum: $2,716,808.00
Project Summary: Researchers will evaluate homocysteine lowering strategies (folate and B vitamin supplementation, or the antioxidant, N-acetylcysteine amide), test the necessity of IL-1 activity and the necessity of microglia in mediating the chemotherapy-associated cognitive deficits, as well as neuroinflammation and oxidative stress, leading to gray and white matter damage, and altered synaptic pruning in the prefrontal cortex.

National Institute on Aging R0A
Title: Regulation of GDF11 by extracellular mechanisms
Project Period: 9/15/2020- 5/31/2025
Award Sum: $2,764,533.00
Project Summary: This study will test the hypothesis that GDF11 and GDF8 exists in multiple ‘activity’ states that regulate a transition from a latent state to an active state, test the hypothesis that the ‘net’ GDF11/GDF8 activity in serum decreases with age, and test the hypothesis that GDF11 signaling and its regulation/extracellular antagonism can be decoupled.

National Institute of General Medical Sciences R35
Title: Utilizing Immune Phenotypes to Prevent Chronic Critical Illness
Project Period: 9/1/2020- 6/30/2025
Award Sum: $2,021,250.00
Project Summary: Successful completion of these studies will significantly advance the field of immune phenotypes and set the groundwork for developing individualized immune therapies for a variety of critically ill patients.

National Heart, Lung and Blood Institute R01
Title: The role of TFEB in aortic aneurysms
Award Period: 6/1/2020- 5/31/2023
Award Sum: $1,616,822.00
Project Summary: Researchers will characterize the protective role of transcription factor-EB (TFEB) in abdominal aortic aneurysm (AAA) and establish nitro-conjugated linoleic acid (CLA) as a novel therapeutic strategy against AAA by targeting vascular smooth muscle cells TFEB. This mechanistic research will set a solid foundation for rapid translation into clinical utilization of nitro-CLA and may lead to a breakthrough for treatment or/and prevention of AAA.
Expand all
Collapse all
Contact Us
University of CincinnatiCollege of Medicine
CARE/Crawley Building
Suite E-870
3230 Eden Avenue
PO Box 670555
Cincinnati, OH 45267-0555
Mail Location: 0555
Phone: 513-558-7333
Fax: 513-558-3512
Email: College of Medicine